Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

2(33.3%)

Phase 2

2(33.3%)

Phase 3

2(33.3%)

6Total

Phase 4(2)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04366908Phase 2Completed

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Role: collaborator

NCT02889510Phase 3Completed

Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT04271839Phase 4Withdrawn

Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients

Role: collaborator

NCT02319135Phase 3Completed

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

NCT01087008Phase 4Completed

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

Role: collaborator

NCT01802450Phase 2Unknown

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Role: collaborator

NCT01717105Unknown

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Role: collaborator

All 7 trials loaded